Form 4: ANI Pharmaceuticals SVP, Chief HR Officer Sells 1,000 Shares Under 10b5-1 Plan

Krista Davis, SVP and Chief HR Officer at ANI Pharmaceuticals, sold 1,000 shares of common stock at $60 per share on December 11, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Krista Davis, the Senior Vice President and Chief Human Resources Officer of ANI Pharmaceuticals, sold 1,000 shares of the company's common stock on December 11, 2024.
• The sale was executed at a price of $60 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted by Ms. Davis on August 23, 2024.
• Following the sale, Ms. Davis directly owns 49,059 shares of ANI Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• Similar filings are regularly made by executives at comparable pharmaceutical companies such as Teva Pharmaceuticals, Mylan, and Perrigo, when they execute pre-planned stock sales.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on investor sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

ANI Pharmaceuticals, insider trading, Form 4, stock sale, Rule 10b5-1, Krista Davis, executive transaction